Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30365566 | 0.85 | L3MBTL1 (0.40) | GSK3AGSK3BPIK3C3JAK2JAK1 | |
| SCHEMBL17840796 | 0.85 | L3MBTL1 (0.40) | GSK3AGSK3BPIK3C3JAK2JAK1 | |
| SCHEMBL17865339 | 0.83 | MET (0.38) | GSK3APIK3C3TGFBR1L3MBTL1GAA | |
| SCHEMBL17840742 | 0.80 | JAK2 (0.41) | PIK3C3JAK2JAK1TYK2L3MBTL1 | |
| SCHEMBL25227856 | 0.75 | GSK3A (0.39) | GSK3AGSK3B | |
| SCHEMBL17840536 | 0.74 | PIK3C3 (0.44) | PIK3C3JAK2JAK1TYK2L3MBTL1 | |
| SCHEMBL17871068 | 0.74 | PIK3C3 (0.38) | PIK3C3JAK2JAK1TYK2L3MBTL1 | |
| SCHEMBL17863758 | 0.74 | PIK3C3 (0.46) | GSK3BPIK3C3JAK2JAK1TYK2 | |
| SCHEMBL17863795 | 0.74 | PIK3C3 (0.49) | PIK3C3TGFBR1L3MBTL1 | |
| SCHEMBL17840637 | 0.74 | L3MBTL1 (0.39) | PIK3C3JAK2JAK1TYK2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | TGFBR2, TGFBR1, TGFB1 | GSK3A 52/4885GSK3B 33/4885PIK3C3 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.